cefixime
Trade name: suprax
Approved
Apr 28, 1989
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall. Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor. Cefixime is sold under the brand name Suprax, indicated for the treatment of: Uncomplicated Urinary Tract Infections Otitis Media Pharyngitis and Tonsillitis Acute Exacerbations of Chronic Bronchitis Uncomplicated Gonorrhea (cervical/urethral) — NCATS
Clinical trial activity
31 trials · 48 clinical orgs · 11 marketing orgs
Earliest trial started Aug 1, 1999 (NCT00004216)
Timeline
1980s
- Apr 28, 1989
Lederle — Earliest FDA Approval
- Apr 28, 1989
Lederle — NDA Organization
- Apr 28, 1989
American Cyanamid — NDA Secondary Org
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
2000s
- Feb 12, 2004
Lupin — Marketing Organization
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
- Oct 25, 2010
Lupin — NDA Secondary Org
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
- Apr 14, 2015
Aurobindo Pharma — Marketing Organization
- Feb 6, 2017
Belcher Pharmaceuticals — Marketing Organization
- Feb 6, 2017
AJENAT PHARMS — Marketing Organization
- Nov 17, 2017
Sandoz — Marketing Organization
- Nov 17, 2017
Chartwell Pharmaceuticals — Marketing Organization
- Nov 17, 2017
Novartis — Marketing Organization
- Oct 9, 2018
Alkem Labs Ltd — Marketing Organization
2020s
- Dec 17, 2024
FDC — Marketing Organization
Indications
Approved for
Studied for
- Bacterial Infections · Phase 4
- Chlamydia · Phase 2
- Dental Pulp · Phase 2/Phase 3
- Diarrhea · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Gonorrhea · Phase 4
- HIV · Phase 3
- Kidney Diseases · Phase 3
- Liver Abscess · Phase 3
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1
- Postoperative Pain · Phase 2/Phase 3
- Renal Insufficiency, Chronic · Phase 3
- Syphilis · Phase 4
- Typhoid Fever · Phase 4
- Urinary Bladder, Neurogenic · Phase 4
- Urinary Tract Infections · Phase 4
- Uterine Cervicitis · Phase 3
- Vaginosis, Bacterial · Phase 3
- Vesico-Ureteral Reflux · Phase 3
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedApr 28, 1989
Chemistry & pharmacology
SMILES
NC1=NC(=CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O- Mol. weight
- 453.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaCefixime ↗
- NCATSXZ7BG04GJX ↗
- ChEMBLCHEMBL1541 ↗
Also known as
- cefixim
- cefixim
- cefixim
- (-)-cefixim
- (-)-cefixim
- cefixima
- cefixima
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- cefixime
- céfixime
- céfixime
- cefiximine
- cefiximum
- cefiximum
- cefixoral
- cefspan
- cefspan
- cl-284635
- cl-284635
- fk-027
- fk-027
- fr-17027
- fr-17027
- oroken
- oroken
- suprax
- suprax
- suprax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06847126 | Phase 3 | Feb 25, 2025 | Postgraduate Institute of Medical Education and Research |
| NCT05294588 | Phase 2 | Apr 18, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT05216744 | Phase 2 | Jul 15, 2021 | Hai Phong Medical University |
| NCT06907316 | Phase 4 | Jul 13, 2021 | Bulovka Hospital, Orebro University |
| NCT04958122 | Phase 3 | Jun 20, 2021 | AIDS Healthcare Foundation, Cayetano Heredia University, University of Southern California |
| NCT06090565 | Phase 4 | Apr 1, 2021 | Bulovka Hospital, Orebro University |
| NCT04349826 | Phase 4 | Sep 1, 2020 | Government of United Kingdom, Medical Research Council, University of Oxford, Wellcome Trust |
| NCT04982861 | N/A | Jun 15, 2020 | PT Bernofarm, PT Pharma Metric Labs, PT. Pharma Metric Labs |
| NCT03969758 | Phase 3 | Jun 30, 2019 | Postgraduate Institute of Medical Education and Research |
| NCT05027893 | N/A | Jun 7, 2019 | University of Novi Sad |
| NCT03752112 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2019 | World Health Organization |
| NCT03660488 | Phase 2 | Sep 30, 2018 | AIDS Healthcare Foundation, University of California, Los Angeles |
| NCT03716804 | Phase 4 | Jun 6, 2018 | Bangladesh Medical University |
| NCT03408392 | Phase 1 | Feb 8, 2018 | GlaxoSmithKline |
| NCT03329547 | Phase 1 | Jan 11, 2018 | GlaxoSmithKline |
| NCT03840811 | Phase 1 | Apr 23, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03084601 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2016 | Cairo University |
| NCT02830230 | N/A | Jul 1, 2016 | HBT Medical College & R.N.Cooper Muncipal Hospital, Tata Memorial Hospital |
| NCT02708992 | Phase 1 | Apr 28, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02596503 | Phase 1 | Oct 1, 2015 | University of Colorado, Denver, University of Kentucky |
Organizations
Research & Development (48)
Marketing (14)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AJENAT PHARMS | For profit | MKTG | Feb 6, 2017 |
| Alkem Labs Ltd | For profit | MKTG | Oct 9, 2018 |
| American Cyanamid | For profit | NDA2 | Apr 28, 1989 |
| Aurobindo Pharma | For profit | MKTG | Apr 14, 2015 |
| Belcher Pharmaceuticals | For profit | SYN | Feb 6, 2017 |
| Belcher Pharmaceuticals | For profit | MKTG | Feb 6, 2017 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 17, 2017 |
| FDC | For profit | MKTG | Dec 17, 2024 |
| Lederle | For profit | NDA | Apr 28, 1989 |
| Lupin | For profit | NDA2 | Oct 25, 2010 |
| Lupin | For profit | MKTG | Feb 12, 2004 |
| Novartis | For profit | MKTG | Nov 17, 2017 |
| Sandoz | For profit | MKTG | Nov 17, 2017 |
| Sandoz | For profit | SYN | Nov 17, 2017 |